Renaissance Technologies Adds $6M in Alignment Healthcare, Inc. ($ALHC)
Renaissance Technologies increased its stake in Alignment Healthcare by 235,900 shares, reflecting confidence in the company.
Key Points
- Renaissance Technologies increased its holdings in Alignment Healthcare by 235,900 shares, bringing its total to 2,903,100 shares as of the latest 13F filing.
- Alignment Healthcare trades on NasdaqGS under the ticker ALHC with a market cap of about $4.43 billion and a forward P/E ratio of 29.6.
- Insider sales at Alignment Healthcare included CEO John Kao selling 298,000 shares on June 10, 2026, as part of a planned transaction.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Renaissance Technologies has increased its stake in Alignment Healthcare, Inc. (NasdaqGS: ALHC), according to its latest Form 13F filing with the SEC. The investment firm added 235,900 shares during the reporting period, bringing its total holdings to 2,903,100 shares. The value of this position is approximately $59.6 million.
What Changed in Renaissance Technologies' Alignment Healthcare Position
Renaissance Technologies boosted its holdings in Alignment Healthcare by 235,900 shares, an increase of about 8.84% from its previous stake. Prior to this change, the firm held 2,667,200 shares. This adjustment reflects a growing confidence in the company's prospects, with the total value of the holdings now standing at $59.6 million.
Other Institutional Activity in Alignment Healthcare
Several other major institutional investors also adjusted their positions in Alignment Healthcare. Wellington Management Group LLP increased its stake by 3,028,043 shares, resulting in a total of 17,098,936 shares valued at approximately $301.3 million. FMR LLC added 1,236,129 shares, bringing its total to 15,892,064 shares worth about $280 million. BlackRock, Inc. grew its holdings by 363,883 shares, ending with 14,075,197 shares valued at $248 million. T. Rowe Price Investment Management, Inc. also increased its position by 503,872 shares, totaling 13,147,656 shares valued at $231.7 million.
Alignment Healthcare, Inc. Stock Up 77.2%
Shares of Alignment Healthcare (NasdaqGS: ALHC) recently traded around $20.53. The company, with a market cap of approximately $4.43 billion, has a forward P/E ratio of 29.6 and a beta of 1.149. Over the past year, the stock has seen a low of $11.63 and a high of $23.87. The 50-day moving average is $18.67, and the 200-day moving average is $18.68. The company maintains a current ratio of 1.58, a quick ratio of 1.385, and a debt-to-equity ratio of 159.49.
Recent Earnings
Alignment Healthcare reported revenue of about $4.26 billion, with a revenue growth rate of 33.3%. The company's net margin is 0.47%, and it has a return on equity of 12.53%. The next earnings release is scheduled for July 30, 2026.
Earnings drift grade
Outlook vs expectations on the last report — not price action.
-
Forward outlook
1 target raises vs 1 cuts.
-
EPS & revenue
EPS beat estimates by 575.7%. Revenue missed estimates by 0.5%.
-
Profit surprise
EBITDA missed by 28 percent. Operating income missed by 3 percent.
-
Pre-earnings setup
Bar was high, analysts already very bullish.
-
Analyst signal
1 target raise, 1 target cut.
-
Earnings quality
Operating margin up 1.8 points. Negative free cash flow.
Earnings Call Summary
Alignment Healthcare reported first quarter 2026 revenue of $1.2 billion, up 33 percent year over year, driven by strong membership growth of 31 percent to 284,800 members. The company beat adjusted EBITDA expectations at $38 million, exceeding guidance range. Management highlighted a temporary January billing issue related to observation versus acute rate payments that caused higher inpatient admissions in early Q1, but stated the problem was internal, quickly resolved by February, and did not signal a systemic flaw. Management remained confident in scaling to 1 million members and emphasized continuous improvement in claims automation, AI deployment, and clinical efficiency.
Guidance Alignment raised its full year revenue guidance to approximately $5.2 billion, up from prior outlook, expecting 31 percent growth. The company also raised adjusted EBITDA guidance, projecting between $138 million and $163 million for 2026. For the second quarter, they guided revenue between $1.3 billion and $1.32 billion and EBITDA of $50 million to $60 million. Management emphasized confidence in delivering the first half at strong margins while continuing investments in automation and clinical infrastructure.
Underwhelming report. Mixed results that may lead to slightly lower expectations.
Insider Buying and Selling at Alignment Healthcare, Inc.
Recent insider transactions at Alignment Healthcare include planned sales by President Dawn Christine Maroney, who sold 30,000 shares on June 15, 2026, and Chief Medical Officer Hyong Kim, who sold 35,951 shares on June 12, 2026. CEO John Kao sold 298,000 shares on June 10, 2026. EVP Joseph Konowiecki sold 25,000 shares on June 11, 2026, but also purchased 122,807 shares on June 3, 2026, in an unplanned transaction.
Analysts Set New Price Targets
Several analysts have maintained their ratings on Alignment Healthcare. On May 26, 2026, Barclays maintained a 'hold' rating with a price target of $16. UBS also maintained a 'hold' rating with a target of $22 on May 1, 2026. JP Morgan had earlier maintained a 'buy' rating with a target of $26 on February 5, 2026. The consensus from 13 analysts is a 'strong buy', with a mean target price of $24.92.
About Alignment Healthcare
Alignment Healthcare, Inc. operates a healthcare platform focused on seniors in the United States, offering Medicare Advantage plans tailored to meet the needs of its customers. Headquartered in Orange, California, and led by CEO John E. Kao, the company was founded in 2013 and employs around 1,849 people. It is part of the healthcare sector, specifically within the healthcare plans industry.
Bottom Line
Renaissance Technologies' increased stake in Alignment Healthcare suggests confidence in the company's future performance. Investors often track such filings to gauge institutional sentiment, though it's important to remember that 13F filings are backward-looking and may not reflect current positions. Alignment Healthcare's stock performance and analyst ratings indicate a positive outlook, supported by a strong market position and growth potential.
Get Alignment Healthcare, Inc. alerts
New 13F filings, insider trades, and analyst moves on $ALHC, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.